353 related articles for article (PubMed ID: 25498484)
1. Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial.
Roberts I; Prieto-Merino D; Manno D
Crit Care; 2014 Dec; 18(6):685. PubMed ID: 25498484
[TBL] [Abstract][Full Text] [Related]
2. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Roberts I; Shakur H; Coats T; Hunt B; Balogun E; Barnetson L; Cook L; Kawahara T; Perel P; Prieto-Merino D; Ramos M; Cairns J; Guerriero C
Health Technol Assess; 2013 Mar; 17(10):1-79. PubMed ID: 23477634
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a prognostic model to predict death in patients with traumatic bleeding, and evaluation of the effect of tranexamic acid on mortality according to baseline risk: a secondary analysis of a randomised controlled trial.
Perel P; Prieto-Merino D; Shakur H; Roberts I
Health Technol Assess; 2013 Jun; 17(24):1-45, v-vi. PubMed ID: 23782457
[TBL] [Abstract][Full Text] [Related]
4. Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the CRASH-3 randomised trial.
Brenner A; Belli A; Chaudhri R; Coats T; Frimley L; Jamaluddin SF; Jooma R; Mansukhani R; Sandercock P; Shakur-Still H; Shokunbi T; Roberts I;
Crit Care; 2020 Nov; 24(1):560. PubMed ID: 33172504
[TBL] [Abstract][Full Text] [Related]
5. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Williams-Johnson JA; McDonald AH; Strachan GG; Williams EW
West Indian Med J; 2010 Dec; 59(6):612-24. PubMed ID: 21702233
[TBL] [Abstract][Full Text] [Related]
6. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
; Roberts I; Shakur H; Afolabi A; Brohi K; Coats T; Dewan Y; Gando S; Guyatt G; Hunt BJ; Morales C; Perel P; Prieto-Merino D; Woolley T
Lancet; 2011 Mar; 377(9771):1096-101, 1101.e1-2. PubMed ID: 21439633
[TBL] [Abstract][Full Text] [Related]
7. Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms.
Roberts I; Edwards P; Prieto D; Joshi M; Mahmood A; Ker K; Shakur H
Trials; 2017 Jan; 18(1):48. PubMed ID: 28143564
[TBL] [Abstract][Full Text] [Related]
8. Antifibrinolytic drugs for acute traumatic injury.
Ker K; Roberts I; Shakur H; Coats TJ
Cochrane Database Syst Rev; 2015 May; 2015(5):CD004896. PubMed ID: 25956410
[TBL] [Abstract][Full Text] [Related]
9. Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial.
Roberts I; Perel P; Prieto-Merino D; Shakur H; Coats T; Hunt BJ; Lecky F; Brohi K; Willett K;
BMJ; 2012 Sep; 345():e5839. PubMed ID: 22968527
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Guerriero C; Cairns J; Perel P; Shakur H; Roberts I;
PLoS One; 2011 May; 6(5):e18987. PubMed ID: 21559279
[TBL] [Abstract][Full Text] [Related]
11. CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested randomised, placebo-controlled trial.
Perel P; Al-Shahi Salman R; Kawahara T; Morris Z; Prieto-Merino D; Roberts I; Sandercock P; Shakur H; Wardlaw J
Health Technol Assess; 2012; 16(13):iii-xii, 1-54. PubMed ID: 22417901
[TBL] [Abstract][Full Text] [Related]
12. Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality.
Prescrire Int; 2013 Jul; 22(140):189-90. PubMed ID: 23951599
[TBL] [Abstract][Full Text] [Related]
13. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
; Shakur H; Roberts I; Bautista R; Caballero J; Coats T; Dewan Y; El-Sayed H; Gogichaishvili T; Gupta S; Herrera J; Hunt B; Iribhogbe P; Izurieta M; Khamis H; Komolafe E; Marrero MA; Mejía-Mantilla J; Miranda J; Morales C; Olaomi O; Olldashi F; Perel P; Peto R; Ramana PV; Ravi RR; Yutthakasemsunt S
Lancet; 2010 Jul; 376(9734):23-32. PubMed ID: 20554319
[TBL] [Abstract][Full Text] [Related]
14. Tranexamic acid for trauma: filling the 'GAP' in evidence.
Mitra B; Mazur S; Cameron PA; Bernard S; Burns B; Smith A; Rashford S; Fitzgerald M; Smith K; Gruen RL;
Emerg Med Australas; 2014 Apr; 26(2):194-7. PubMed ID: 24708011
[TBL] [Abstract][Full Text] [Related]
15. Tranexamic acid for trauma patients: a critical review of the literature.
Cap AP; Baer DG; Orman JA; Aden J; Ryan K; Blackbourne LH
J Trauma; 2011 Jul; 71(1 Suppl):S9-14. PubMed ID: 21795884
[TBL] [Abstract][Full Text] [Related]
16. Tranexamic Acid Update in Trauma.
Ramirez RJ; Spinella PC; Bochicchio GV
Crit Care Clin; 2017 Jan; 33(1):85-99. PubMed ID: 27894501
[TBL] [Abstract][Full Text] [Related]
17. Antifibrinolytic drugs for acute traumatic injury.
Roberts I; Shakur H; Ker K; Coats T;
Cochrane Database Syst Rev; 2012; 12():CD004896. PubMed ID: 23418644
[TBL] [Abstract][Full Text] [Related]
18. Tranexamic acid for acute gastrointestinal bleeding (the HALT-IT trial): statistical analysis plan for an international, randomised, double-blind, placebo-controlled trial.
Brenner A; Afolabi A; Ahmad SM; Arribas M; Chaudhri R; Coats T; Cuzick J; Gilmore I; Hawkey C; Jairath V; Javaid K; Kayani A; Mutti M; Nadeem MA; Shakur-Still H; Stanworth S; Veitch A; Roberts I;
Trials; 2019 Jul; 20(1):467. PubMed ID: 31362765
[TBL] [Abstract][Full Text] [Related]
19. Antifibrinolytic drugs for acute traumatic injury.
Roberts I; Shakur H; Ker K; Coats T;
Cochrane Database Syst Rev; 2011 Jan; (1):CD004896. PubMed ID: 21249666
[TBL] [Abstract][Full Text] [Related]
20. Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data.
Nutbeam T; Roberts I; Weekes L; Shakur-Still H; Brenner A; Ageron FX
Br J Anaesth; 2022 Aug; 129(2):191-199. PubMed ID: 35597623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
